Posted by Michael Wonder on 19 May 2023
FDA approves first topical gene therapy for treatment of wounds in patients with dystrophic epidermolysis bullosa
19 May 2023 - Today, the US FDA approved Vyjuvek, a herpes-simplex virus type 1 vector-based gene therapy, for the treatment of wounds in patients 6 months of age and older with dystrophic epidermolysis bullosa with mutation(s) in the collagen type VII alpha 1 chain (COL7A1) gene.
Vyjuvek is a genetically modified (engineered in a laboratory) herpes-simplex virus used to deliver normal copies of the COL7A1 gene to the wounds.
